Key Highlights

  • The 2024 IPO sold 23,000,000 units, each pairing a Class A share with a right to one-tenth of a share.
  • Net income for the quarter ended June 30 was $1,980,048; the trust held $246,845,170, or $10.73 per public share.
  • The company has until December 11, 2026 to complete a business combination, and the filing flags going-concern doubt.
  • The NYSE accepted a plan on April 29 to cure a public-holder shortfall; the plan period ends August 6, 2027.

Jackson Acquisition Company II (NYSE:JACS) shares were trading near their 52-week high at USD 10.83 on October 19, 2026, up 0.19%. The Cayman Islands blank check company has not named a target, and its filings turn on a single date: December 11, 2026, the deadline to complete an initial business combination. The trust account held $246,845,170 on June 30, and a February notice from the New York Stock Exchange about the number of public stockholders led to a plan period that runs to August 6, 2027.

A $230 million healthcare-focused shell built on units and rights

The company closed its initial public offering on December 11, 2024, selling 23,000,000 units at $10.00, including the full 3,000,000-unit over-allotment, for gross proceeds of $230 million. Each unit pairs one Class A ordinary share with one right to receive one-tenth of a Class A share when a business combination is completed. The units carry no warrants. At closing, $232.3 million, or $10.10 per unit, went into the trust account. The prospectus named RJ Healthcare SPAC II, LLC as sponsor, with Jackson Investment Group, controlled by Richard Jackson, as its sole member and manager. The company may pursue a target in any industry but intends to focus on healthcare services, healthcare technology and other healthcare businesses.

June quarter: trust income and going-concern doubt

For the quarter ended June 30, 2026, the company reported net income of $1,980,048, or $0.07 per Class A and Class B share: $2,164,627 of income on trust investments less $184,579 of general and administrative costs. Six-month net income was $3,949,131, against $4,545,737 a year earlier.

The trust held $246,845,170 at June 30, up from $242,543,188 at year-end, and the filing carries the public shares at a redemption value of $10.73 each, versus $10.55 at year-end. Cash outside the trust was $358,338, down from $521,776, and the company reported a working capital deficit of $132,101.

Management concluded that the mandatory liquidation that would follow a missed December 11, 2026 deadline raises substantial doubt about the company's ability to continue as a going concern. It points to possible debt or equity financing, with no assurance of success. Disclosure controls were concluded to be effective as of June 30, 2026.

The NYSE notice and the December 11 deadline

On February 6, 2026, the NYSE notified the company that it had fallen below the 300 public stockholders required by Section 802.01B of its Listed Company Manual. The company disclosed this in a Form 8-K filed on February 10. The NYSE accepted its compliance plan on April 29, allowing continued listing through a plan period that ends August 6, 2027. The June quarter report says the plan depends heavily on the announcement or completion of a contemplated business combination and that continued listing is not assured. Failure to meet the requirements would lead the NYSE to begin suspension and delisting procedures.

The company has until December 11, 2026, 24 months from the IPO closing, to complete a business combination. Otherwise it will redeem 100% of the public shares within 10 business days, paid from the trust including interest, less up to $100,000 of interest for dissolution expenses, and the rights would expire worthless. Shareholders can approve an extension, and the annual report filed March 20, 2026 said the company did not currently intend to seek one but might in the future.

Outlook: dates, not results

Neither the annual report nor the June quarter report names a target, a letter of intent or a definitive agreement. The milestones in the filings are dates: December 11, 2026 for the deadline and August 6, 2027 for the end of the NYSE plan period. Those are the company's disclosures, not forecasts by this article, and the filings give no assurance that a deal, an extension or continued listing will follow.